| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eloxx Pharmaceuticals Inc. | ELX-02 | Cystinosis | Phase 2 | Intravenous | Genetic Disorder | |
| Eloxx Pharmaceuticals Inc. | ELX-02 | Alport syndrome | Phase 2 | Intravenous | Genetic Disorder | |
| Emergent BioSolutions Inc. | COVID-EIG | COVID-19 | Phase 2 | Trial Planned | Intramuscular | COVID-19 |
| Enanta Pharmaceuticals Inc. | zelicapavir (EDP-938) (RSVP) | Respiratory Syncytial Virus (community-acquired) | Phase 2b | Ongoing | oral | Respiratory |
| Enanta Pharmaceuticals Inc. | EDP-235 - (SPRINT) | COVID-19 | Phase 2 | Data Released | oral | COVID-19 |
| Enanta Pharmaceuticals Inc. | Zelicapavir (EDP-938) - (RSVHR) | Respiratory Syncytial Virus Infections (RSV) | Phase 2b | Data Released | Oral | Respiratory |
| Enanta Pharmaceuticals Inc. | EDP-305 INTREPID | Primary biliary cholangitis (PBC) | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Enanta Pharmaceuticals Inc. | EDP-305 - (ARGON-2) | Non-alcoholic steatohepatitis (NASH) | Phase 2b | Trial Discontinued | Oral | Gastroenterology |